Quisitive Technology Solutions, Inc. (QUISF) Research

Quisitive Technology Solutions, Inc., through its various subsidiaries, primarily delivers Microsoft-focused technology solutions across North America. Its foundational offerings encompass key Microsoft cloud services, including Azure, Dynamics business applications, and Microsoft 365. The company also develops and markets its own specialized software: CRG emPerform, an employee performance management system tailored for small and medium-sized businesses, and LedgerPay, a comprehensive payment processing platform. Additionally, Quisitive integrates and implements business solutions from other technology partners that complement the Microsoft ecosystem. Beyond these, the company's expertise spans custom application development, advanced business applications, data analytics, holistic digital transformation initiatives, modern digital workplace environments, and robust infrastructure solutions. It further provides cloud managed services, covering essential system administration, vigilant monitoring, application maintenance, configurations, and upgrades. Quisitive’s services cater to a broad spectrum of industries, including healthcare, retail, manufacturing, and public sector organizations. Previously known as Nebo Capital Corp., the company rebranded as Quisitive Technology Solutions, Inc. in August 2018. Its corporate headquarters are situated in Toronto, Canada.

Market snapshot

Symbol
QUISF
Price
$0.39
Day change
0.00%
Market cap
$109.5M
P/E ratio
-1.70x
52-week range
0.183-0.399
Sector
Technology
Industry
Information Technology Services

Peer companies

  • Firefly Neuroscience, Inc. (AIFF)
  • Bigtincan Holdings Limited (BTGHF)
  • Firstwave Cloud Technology Limited (FCLOF)
  • FingerTango Inc. (FGRTF)
  • Huddly AS (HUDLF)
  • ikeGPS Group Limited (IKGPF)
  • Startech Labs, Inc. (LAAB)
  • Net One Systems Co., Ltd. (NONEY)

Open Quisitive Technology Solutions, Inc. (QUISF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.